Humana (HUM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Mar, 2026Executive summary
Annual Meeting scheduled for April 16, 2026, at 1:00 p.m. ET via live webcast for shareholder participation.
Voting materials, including the proxy statement and annual report, are available online or by request, with voting open until April 15, 2026, at 11:59 p.m. ET.
Record date for voting eligibility is February 27, 2026; shareholders and 401(k) plan participants can vote on all proposals.
Voting matters and shareholder proposals
Election of ten directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of PricewaterhouseCoopers LLP as independent auditor is recommended for approval.
Advisory vote on executive compensation (say-on-pay) is recommended for approval.
Approval of the 2026 Stock Incentive Plan is recommended.
Shareholder proposal to require approval for excessive golden parachutes is not recommended by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Proxies are authorized to vote on any other matters that may arise at the meeting.
Latest events from Humana
- Margin targets, quality membership growth, and strategic acquisitions drive long-term outlook.HUM
Leerink Global Healthcare Conference 202610 Mar 2026 - Proxy covers director elections, executive pay, new stock plan, and ESG priorities.HUM
Proxy Filing6 Mar 2026 - Annual meeting covers director elections, compensation, new equity plan, and ESG progress.HUM
Proxy Filing6 Mar 2026 - FY 2025 adjusted EPS hit $17.14; 2026 guidance sees $9.00 EPS amid Stars headwinds.HUM
Q4 202511 Feb 2026 - Net income declined 29% as higher Medicare Advantage costs offset strong revenue growth.HUM
Q2 20242 Feb 2026 - Stabilized utilization, strategic plan exits, and conservative risk management support 2025 outlook.HUM
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Revenue and MA membership rose, but EPS fell as higher medical costs pressured margins.HUM
Q3 202417 Jan 2026 - 2024 adjusted EPS $16.21; 2025 guidance flat; Medicare Advantage to decline 10%.HUM
Q4 20248 Jan 2026 - Q1 2025 Adjusted EPS rose to $11.58, with FY 2025 guidance reaffirmed at $16.25.HUM
Q1 202527 Dec 2025